PMID- 23375850
OWN - NLM
STAT- MEDLINE
DCOM- 20131125
LR  - 20220409
IS  - 1873-460X (Electronic)
IS  - 1056-8727 (Linking)
VI  - 27
IP  - 3
DP  - 2013 May-Jun
TI  - The potential of sodium glucose cotransporter 2 (SGLT2) inhibitors to reduce 
      cardiovascular risk in patients with type 2 diabetes (T2DM).
PG  - 280-6
LID - S1056-8727(12)00341-8 [pii]
LID - 10.1016/j.jdiacomp.2012.12.004 [doi]
AB  - Type 2 diabetes mellitus (T2DM) significantly increases morbidity and mortality 
      from cardiovascular disease (CVD). Treatments for patients with T2DM have the 
      potential to reduce cardiovascular (CV) risk. This review focuses on the 
      potential of a new class of antidiabetic agents, the sodium glucose cotransporter 
      2 (SGLT2) inhibitors, to reduce CV risk in patients with T2DM through reductions 
      in hyperglycemia, blood pressure (BP), and body weight. The results of clinical 
      trials of SGLT2 inhibitors are summarized and discussed.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
FAU - Basile, Jan N
AU  - Basile JN
AD  - Seinsheimer Cardiovascular Health Program, Medical University of South Carolina, 
      Charleston, SC 29425, USA. basilejn@musc.edu
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20130201
PL  - United States
TA  - J Diabetes Complications
JT  - Journal of diabetes and its complications
JID - 9204583
RN  - 0 (Drugs, Investigational)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Membrane Transport Modulators)
RN  - 0 (Sodium-Glucose Transporter 2)
RN  - 0 (Sodium-Glucose Transporter 2 Inhibitors)
SB  - IM
MH  - Animals
MH  - Cardiovascular Diseases/complications/epidemiology/metabolism/*prevention & 
      control
MH  - Diabetes Mellitus, Type 2/*drug therapy/metabolism
MH  - Diabetic Angiopathies/epidemiology/metabolism/*prevention & control
MH  - Diabetic Cardiomyopathies/epidemiology/metabolism/*prevention & control
MH  - Drugs, Investigational/adverse effects/pharmacology/therapeutic use
MH  - Humans
MH  - Hypoglycemic Agents/adverse effects/pharmacology/*therapeutic use
MH  - Membrane Transport Modulators/adverse effects/pharmacology/*therapeutic use
MH  - Risk Factors
MH  - Sodium-Glucose Transporter 2/metabolism
MH  - *Sodium-Glucose Transporter 2 Inhibitors
EDAT- 2013/02/05 06:00
MHDA- 2013/12/16 06:00
CRDT- 2013/02/05 06:00
PHST- 2012/12/10 00:00 [received]
PHST- 2012/12/18 00:00 [accepted]
PHST- 2013/02/05 06:00 [entrez]
PHST- 2013/02/05 06:00 [pubmed]
PHST- 2013/12/16 06:00 [medline]
AID - S1056-8727(12)00341-8 [pii]
AID - 10.1016/j.jdiacomp.2012.12.004 [doi]
PST - ppublish
SO  - J Diabetes Complications. 2013 May-Jun;27(3):280-6. doi: 
      10.1016/j.jdiacomp.2012.12.004. Epub 2013 Feb 1.